Abstract
Cardiovascular disorders are the most common diseases all over the world, which have limitations in the current treatment stratergies. As two subtypes of potassium channel, KCa and KATP ion channels are playing important roles in the occurrence and development of cardiovascular diseases. KCa by activating the signal pathway of c-Src/PI3-kinase/Akt-dependent or eNOS-NO-cGMP effects the function of vascular endothelial cell, while KATP acting as a medium combines the cell electrical activity and energy metabolism. Thus, through acting on KCa or/and KATP, some drugs can play roles in these cardiovascular diseases. Nevertheless, specific and effective western medicines selectively working on these two channels are not identified at present. Some Chinese herbal medicines or bioactive ingredients in contrast have been discovered to be safe and effective in the regulation of the two recently. Therefore, this review article summarized some single herbs and bioactive ingredients targeting KCa or/and KATP ion channels in the management of cardiovascular diseases, with the purpose of demonstrating the alternative treatment of these diseases in perspective of Traditional Chinese medicine.
Keywords: Bioactive ingredients, cardiovascular diseases, chinese herbal medicines, KCa, KATP potassium channels.
Current Pharmaceutical Design
Title:The Role of Chinese Herbal Medicines and Bioactive Ingredients Targeting Myocardial KCa and KATP Channels in Cardiovascular Diseases
Volume: 23 Issue: 7
Author(s): Yan Dong, Pengqian Wang, Xue Feng, Bing Li, Zhong Wang*Haixia Li*
Affiliation:
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Dongzhimennei, Beijing,China
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing,China
Keywords: Bioactive ingredients, cardiovascular diseases, chinese herbal medicines, KCa, KATP potassium channels.
Abstract: Cardiovascular disorders are the most common diseases all over the world, which have limitations in the current treatment stratergies. As two subtypes of potassium channel, KCa and KATP ion channels are playing important roles in the occurrence and development of cardiovascular diseases. KCa by activating the signal pathway of c-Src/PI3-kinase/Akt-dependent or eNOS-NO-cGMP effects the function of vascular endothelial cell, while KATP acting as a medium combines the cell electrical activity and energy metabolism. Thus, through acting on KCa or/and KATP, some drugs can play roles in these cardiovascular diseases. Nevertheless, specific and effective western medicines selectively working on these two channels are not identified at present. Some Chinese herbal medicines or bioactive ingredients in contrast have been discovered to be safe and effective in the regulation of the two recently. Therefore, this review article summarized some single herbs and bioactive ingredients targeting KCa or/and KATP ion channels in the management of cardiovascular diseases, with the purpose of demonstrating the alternative treatment of these diseases in perspective of Traditional Chinese medicine.
Export Options
About this article
Cite this article as:
Dong Yan, Wang Pengqian, Feng Xue, Li Bing, Wang Zhong*, Li Haixia*, The Role of Chinese Herbal Medicines and Bioactive Ingredients Targeting Myocardial KCa and KATP Channels in Cardiovascular Diseases, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612823666161122141755
DOI https://dx.doi.org/10.2174/1381612823666161122141755 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension in Hemodialysis Patients
Current Hypertension Reviews The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Prolyl Hydroxylase Domain-2 Silencing Induced by Hydrodynamic Limb Vein Injection Enhances Vascular Regeneration in Critical Limb Ischemia Mice through Activation of Multiple Genes
Current Gene Therapy MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Gene Therapy in Liver Ischemia and Reperfusion Injury
Current Pharmaceutical Design Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy Subject index to volume 3
Current Molecular Medicine Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets